ArticleNature biotechnology2025
Continuous multiplexed phage genome editing using recombitrons.
Article in Nature biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Discovery and engineering of retrons for precise genome editing.Nature biotechnology · 2026Article
- Mechanistic insights into activation of bacterial Retron-Eco8 immunity by phage protein SSB.Nature communications · 2026Article
- Genome editing of phylogenetically distinct bacteria using cross-species retron-mediated recombineering.Nature biotechnology · 2026Article
- Diversity-generating retroelements for programmable targeted hypermutagenesis.Nature biotechnology · 2026Article
- Diversity-generating retroelements for programmable targeted hypermutagenesis.Nature biotechnology · 2026Article
- Phage-assisted evolution of allosteric protein switches.Nature communications · 2026Article
- Cross-order detection of bacteriophage transduction in microbial communities using RNA barcoding.Nature communications · 2026Article
- Structure and mechanism of antiphage retron Eco2.Nature structural & molecular biology · 2026Article
- The Role of Genomics in Advancing and Standardising Bacteriophage Therapy.Antibiotics (Basel, Switzerland) · 2026Review
- Structural mechanism of the Retron-Eco7 anti-phage defense system.Nature communications · 2025Article
- Structurally related phage helicases trigger type III-A3 retron-mediated anti-phage defense across diverse tailed phage families.Nucleic acids research · 2025Article
- New retron systems from environmental bacteria identify triggers of anti-phage defense and expand tools for genome editing.PLoS biology · 2025Article
- Structural basis of the RNA-mediated Retron-Eco2 oligomerization.Cell discovery · 2025Article
- Disassembly activates Retron-Septu for antiphage defense.Science (New York, N.Y.) · 2025Article
- Phage genome engineering with retrons.Nature biotechnology · 2025Article
- Synthetic and Functional Engineering of Bacteriophages: Approaches for Tailored Bactericidal, Diagnostic, and Delivery Platforms.Molecules (Basel, Switzerland) · 2025Review
- The Application of DNA Viruses to Biotechnology.Viruses · 2025Review
- High throughput variant libraries and machine learning yield design rules for retron gene editors.Nucleic acids research · 2025Article
- Controlling and controlled elements: highlights of the year in mobile DNA research.Mobile DNA · 2024Article
- Simultaneous multi-site editing of individual genomes using retron arrays.Nature chemical biology · 2024Article
Corrections and comments
- Update of
Authors and funding
8 authors.
Funding
Abstract
Bacteriophage genome editing can enhance the efficacy of phages to eliminate pathogenic bacteria in patients and in the environment. However, current methods for editing phage genomes require laborious screening, counterselection or in vitro construction of modified genomes. Here, we present a scalable approach that uses modified bacterial retrons called recombitrons to generate recombineering donor DNA paired with single-stranded binding and annealing proteins for integration into phage genomes. This system can efficiently create genome modifications in multiple phages without the need for counterselection. The approach also supports larger insertions and deletions, which can be combined with simultaneous counterselection for >99% efficiency. Moreover, we show that the process is continuous, with more edits accumulating the longer the phage is cultured with the host, and multiplexable. We install up to five distinct mutations on a single lambda phage genome without counterselection in only a few hours of hands-on time and identify a residue-level epistatic interaction in the T7 gp17 tail fiber.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.